超局灶挽救性高剂量率近距离放疗后前列腺癌患者健康相关生活质量
本研究纳入100例放疗后局部复发前列腺癌患者,采用超局灶挽救性高剂量率近距离放疗(HDR-BT),用EORTC QLQ-PR25问卷评估健康相关生活质量(HR-QoL)。中位随访20个月,结果显示肠道症状影响轻微,但泌尿症状和性功能出现临床相关恶化(最大差值分别为11和12分);基线评分较好者影响较小,尿道剂量≥16 Gy可预测泌尿症状加重。
要点
- 超局灶挽救性HDR-BT对肠道症状影响轻微,但泌尿症状和性功能出现临床相关恶化。
- 基线泌尿和性功能较好的患者,治疗后HR-QoL影响较小。
- 尿道剂量≥16 Gy可预测泌尿症状加重,应密切监测尿道剂量约束。
核心结论
- 超局灶挽救性HDR-BT对肠道症状影响可忽略,但会影响泌尿症状和性功能。
- 基线泌尿和性功能较好的患者 predicted 影响较低。
- 应密切监测尿道剂量约束。
研究设计与样本
- 研究纳入100例接受超局灶挽救性HDR-BT治疗的患者。
- 采用EORTC QLQ-PR25问卷评估前列腺癌相关HR-QoL, domains 包括泌尿症状、肠道症状和性活动/功能。
- 对每个领域建立混合效应模型估计HR-QoL随时间的变化趋势。
- 对显示临床相关变化(≥10分差异)的领域,使用混合效应模型探索潜在预测因素(年龄、基线HR-QoL评分、T分期、肿瘤位置、CTV大小、危及器官剂量和ADT史)。
主要发现
- 中位随访20个月(IQR 13-30),平均问卷应答率86%(范围72-100%)。
- 基线中位评分:泌尿症状12分,肠道症状0分,性活动/功能67/50分。
- 泌尿症状和性功能随时间出现临床相关恶化,最大差值分别为11分和12分。
- 基线评分较差和尿道接受剂量较高(≥16 Gy)可预测泌尿症状加重(p < 0.01 和 p = 0.03)。
- 基线评分较好可预测更好的性功能(p < 0.01)。
关键数值与推荐
- 临床相关变化定义为≥10分差异。
- 尿道接受剂量≥16 Gy可预测泌尿症状加重(p = 0.03)。
- 基线评分较差可预测泌尿症状加重(p < 0.01)。
- 基线评分较好可预测更好的性功能(p < 0.01)。
临床怎么用
- 超局灶挽救性HDR-BT可用于放疗后局部复发前列腺癌,但需关注泌尿症状和性功能影响。
- 治疗前应评估基线泌尿和性功能,基线较好者治疗后HR-QoL影响可能较小。
- 应密切监测尿道剂量约束,尿道剂量≥16 Gy时泌尿症状加重风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For patients with a localized prostate cancer recurrence after radiotherapy, focal salvage treatment offers a less toxic alternative to whole-gland treatments, with the potential of preserving health-related quality of life (HR-QoL). With a focus on the patient's perspective of treatment, this study aims to describe HR-QoL after ultrafocal salvage high-dose-rate brachytherapy (HDR-BT), and to explore predictive factors affecting HR-QoL. MATERIAL AND METHODS: We included 100 patients treated with ultrafocal salvage HDR-BT. Prostate cancer-related HR-QoL was assessed by the EORTC QLQ-PR25 questionnaire. Domains were urinary symptoms, bowel symptoms and sexual activity/functioning. For each domain, a mixed effects model was made to estimate HR-QoL trends over time. For domains showing clinically relevant change (≥10 points difference), the mixed effects model was used to explore potential predictors (age, baseline HR-QoL score, T-stage, tumor location, CTV size, dose to organs at risk and history of ADT). RESULTS: Median follow-up was 20 months (IQR 13-30). Mean questionnaire response rate was 86% (range 72-100%). Median baseline scores were 12 (urinary), 0 (bowel) and 67/50 (sexual activity/functioning). Urinary symptoms and sexual functioning showed clinically relevant deterioration over time (maximum difference of 11 and 12 points, respectively). Worse baseline score and higher administered dose to the urethra (≥16 Gy) were predictive of increased urinary symptoms (p < 0.01 and p = 0.03). Better baseline score was predictive of better sexual functioning (p < 0.01). CONCLUSION: Ultrafocal salvage HDR-BT has negligible impact on bowel symptoms but does affect urinary symptoms and sexual functioning. Lower impact is predicted for patients with favorable urinary and sexual function at baseline. Urethral dose constraints should be closely monitored.
引用
- van Son M, Monninkhof E, Peters M, et al. Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspective. Clin Transl Radiat Oncol. 2020. PMID: 33134565. doi:10.1016/j.ctro.2020.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。